Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.